137 related articles for article (PubMed ID: 23897585)
1. Circulating pro-surfactant protein B as a risk biomarker for lung cancer.
Taguchi A; Hanash S; Rundle A; McKeague IW; Tang D; Darakjy S; Gaziano JM; Sesso HD; Perera F
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1756-61. PubMed ID: 23897585
[TBL] [Abstract][Full Text] [Related]
2. Pro-surfactant protein B as a biomarker for lung cancer prediction.
Sin DD; Tammemagi CM; Lam S; Barnett MJ; Duan X; Tam A; Auman H; Feng Z; Goodman GE; Hanash S; Taguchi A
J Clin Oncol; 2013 Dec; 31(36):4536-43. PubMed ID: 24248694
[TBL] [Abstract][Full Text] [Related]
3. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.
Wikoff WR; Hanash S; DeFelice B; Miyamoto S; Barnett M; Zhao Y; Goodman G; Feng Z; Gandara D; Fiehn O; Taguchi A
J Clin Oncol; 2015 Nov; 33(33):3880-6. PubMed ID: 26282655
[TBL] [Abstract][Full Text] [Related]
4. Gene polymorphisms of SFTPB rs7316, rs9752 and PAOX rs1046175 affect the diagnostic value of plasma Pro-SFTPB and DAS in Chinese Han non-small-cell lung cancer patients.
Wang K; Huang Q; Zhao G; Yang J; Yang K; Huang Y
J Cell Biochem; 2019 Sep; 120(9):14804-14812. PubMed ID: 31016788
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
; Guida F; Sun N; Bantis LE; Muller DC; Li P; Taguchi A; Dhillon D; Kundnani DL; Patel NJ; Yan Q; Byrnes G; Moons KGM; Tjønneland A; Panico S; Agnoli C; Vineis P; Palli D; Bueno-de-Mesquita B; Peeters PH; Agudo A; Huerta JM; Dorronsoro M; Barranco MR; Ardanaz E; Travis RC; Byrne KS; Boeing H; Steffen A; Kaaks R; Hüsing A; Trichopoulou A; Lagiou P; La Vecchia C; Severi G; Boutron-Ruault MC; Sandanger TM; Weiderpass E; Nøst TH; Tsilidis K; Riboli E; Grankvist K; Johansson M; Goodman GE; Feng Z; Brennan P; Johansson M; Hanash SM
JAMA Oncol; 2018 Oct; 4(10):e182078. PubMed ID: 30003238
[TBL] [Abstract][Full Text] [Related]
6. Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer.
Ruhaak LR; Stroble C; Dai J; Barnett M; Taguchi A; Goodman GE; Miyamoto S; Gandara D; Feng Z; Lebrilla CB; Hanash S
Cancer Prev Res (Phila); 2016 Apr; 9(4):317-23. PubMed ID: 26813970
[TBL] [Abstract][Full Text] [Related]
7. Plasma pro-surfactant protein B and lung function decline in smokers.
Leung JM; Mayo J; Tan W; Tammemagi CM; Liu G; Peacock S; Shepherd FA; Goffin J; Goss G; Nicholas G; Tremblay A; Johnston M; Martel S; Laberge F; Bhatia R; Roberts H; Burrowes P; Manos D; Stewart L; Seely JM; Gingras M; Pasian S; Tsao MS; Lam S; Sin DD;
Eur Respir J; 2015 Apr; 45(4):1037-45. PubMed ID: 25614175
[TBL] [Abstract][Full Text] [Related]
8. Experimental study of peripheral-blood pro-surfactant protein B for screening non-small cell lung cancer.
He Y; Jiang Z; Tong F; Li M; Yin X; Hu S; Wang L
Acta Cir Bras; 2017 Jul; 32(7):568-575. PubMed ID: 28793041
[TBL] [Abstract][Full Text] [Related]
9. Prediction of lung cancer risk using circulating pro-surfactant protein B and high-sensitivity C-reactive protein among Egyptian workers in the rubber industry.
Mourad BH
Toxicol Ind Health; 2020 Apr; 36(4):237-249. PubMed ID: 32419650
[TBL] [Abstract][Full Text] [Related]
10. Serum pro-surfactant protein B is correlated with clinical properties in osteosarcoma patients.
Feng S; Fu D; Zhang Y; Zhang L; Ji Y; Li H; A L
Biochem Cell Biol; 2023 Oct; 101(5):456-463. PubMed ID: 37192548
[TBL] [Abstract][Full Text] [Related]
11. beta-carotene-induced changes in RARbeta isoform mRNA expression patterns do not influence lung adenoma multiplicity in the NNK-initiated A/J mouse model.
Goralczyk R; Bachmann H; Wertz K; Lenz B; Riss G; Buchwald Hunziker P; Greatrix B; Aebischer CP
Nutr Cancer; 2006; 54(2):252-62. PubMed ID: 16898870
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer.
Pine SR; Mechanic LE; Enewold L; Chaturvedi AK; Katki HA; Zheng YL; Bowman ED; Engels EA; Caporaso NE; Harris CC
J Natl Cancer Inst; 2011 Jul; 103(14):1112-22. PubMed ID: 21685357
[TBL] [Abstract][Full Text] [Related]
13. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.
Spitz MR; Barnett MJ; Goodman GE; Thornquist MD; Wu X; Pollak M
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1413-8. PubMed ID: 12433720
[TBL] [Abstract][Full Text] [Related]
14. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
Sestini S; Boeri M; Marchiano A; Pelosi G; Galeone C; Verri C; Suatoni P; Sverzellati N; La Vecchia C; Sozzi G; Pastorino U
Oncotarget; 2015 Oct; 6(32):32868-77. PubMed ID: 26451608
[TBL] [Abstract][Full Text] [Related]
15. Prediagnostic levels of serum beta-cryptoxanthin and retinol predict smoking-related lung cancer risk in Shanghai, China.
Yuan JM; Ross RK; Chu XD; Gao YT; Yu MC
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):767-73. PubMed ID: 11440962
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of plasma levels of coenzyme Q10 and lung cancer risk in a low-income population in the Southeastern United States.
Shidal C; Yoon HS; Zheng W; Wu J; Franke AA; Blot WJ; Shu XO; Cai Q
Cancer Med; 2021 Feb; 10(4):1439-1447. PubMed ID: 33547884
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.
Yu H; Spitz MR; Mistry J; Gu J; Hong WK; Wu X
J Natl Cancer Inst; 1999 Jan; 91(2):151-6. PubMed ID: 9923856
[TBL] [Abstract][Full Text] [Related]
18. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance.
Albanes D; Heinonen OP; Taylor PR; Virtamo J; Edwards BK; Rautalahti M; Hartman AM; Palmgren J; Freedman LS; Haapakoski J; Barrett MJ; Pietinen P; Malila N; Tala E; Liippo K; Salomaa ER; Tangrea JA; Teppo L; Askin FB; Taskinen E; Erozan Y; Greenwald P; Huttunen JK
J Natl Cancer Inst; 1996 Nov; 88(21):1560-70. PubMed ID: 8901854
[TBL] [Abstract][Full Text] [Related]
19. Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker study.
Carozzi FM; Bisanzi S; Carrozzi L; Falaschi F; Lopes Pegna A; Mascalchi M; Picozzi G; Peluso M; Sani C; Greco L; Ocello C; Paci E;
Int J Cancer; 2017 Jul; 141(1):94-101. PubMed ID: 28387927
[TBL] [Abstract][Full Text] [Related]
20. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls.
Yoon KA; Park S; Lee SH; Kim JH; Lee JS
J Mol Diagn; 2009 May; 11(3):182-5. PubMed ID: 19324991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
